Drug Type Small molecule drug |
Synonyms 2-(N-Benzylanilinomethyl)-2-imidazoline, 2-(N-Phenyl-N-benzylaminomethyl)imidazoline, 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine + [2] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC17H20ClN3 |
InChIKeySWKDMSRRIBZZAY-UHFFFAOYSA-N |
CAS Registry2508-72-7 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D07459 | Antazoline Hydrochloride |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Arrhythmias, Cardiac | China | - | |
| Hypersensitivity | China | - |
Phase 4 | 74 | mvbrhnrezy(wpzkebvhge) = ucsvcioawo xwsgifrxde (gwbtjjtaez ) | Positive | 01 Oct 2017 | |||
Placebo | mvbrhnrezy(wpzkebvhge) = mrguqmzerh xwsgifrxde (gwbtjjtaez ) |





